Dr Seth has been working in the field of Virology since 1968. Terri Warren, RN, and Ricks Warren, PhD, The Updated herpes cure soon to come Handbook, Portland Press, 2002. The pace of discovery has continued in recent years with the development of more rapid DNA amplification techniques that do not require postamplification analysis using amplified products (real-time PCR). The gD2t-AS04 vaccine has been demonstrated to be safe in several large clinical trials. 12 7451-7461 Newswise — ST. LOUIS – Saint Louis University research findings published in the December issue of Antimicrobial Agents and Chemotherapy report a family of molecules known as nucleotidyltransferase superfamily (NTS) enzyme inhibitors are promising candidates for new herpes virus treatments. It is under preclinical trials in non-human primates for its efficacy.
Would Cory testify? Morrison Ph.D., professor of Molecular Microbiology and Immunology at Saint Louis University, likened a combination of treatments for herpes to a cocktail of medications HIV patients take. Lead author John E. Tavis, Ph.D., professor of Molecular Microbiology and Immunology at Saint Louis University, noted the findings, which first appeared online in September, have already received interest from pharmacology firms. “Within a decade or so, we could have therapies that reasonably improve patient outcomes,” Tavis said. He has been able to introduce the Polymerase Chain Reaction as a rapid assay for the diagnosis of tuberculosis particularly extrapulmonary tuberculosis and HIV infection in newborns. The Game is Rigged: Why sex that’s consensual can still be bad.
Herpes can be passed from mother to child during childbirth posing serious health risks to both the baby and the new mother. HSV-2 also increases the risk of human immunodeficiency virus (HIV) acquisition. The research team at Saint Louis University investigated whether inhibitors of NTS enzymes would suppress replication of HSV-1 and HSV-2. The inhibitors suppressed accumulation of viral genomes and infectious particles and blocked events in the viral replication cycle before and during viral DNA replication. Five of six NTS inhibitors of the HSVs also blocked replication of another herpes virus pathogen, human cytomegalovirus. Patricia Essex and Dr. He noted that one compound has already proven effective in animals and another is found in a topical antifungal already FDA approved for use.
Current treatment of herpes infections relies primarily on nucleoside analog inhibitors of the viral DNA polymerase, according to the article. Several newer agents are in clinical development, but none of them have been shown to fully suppress herpes infections. Other authors include Hong Wang, Ann E. Tollefson, Baoling Ying, Maria Korom, Xiaohong Cheng, Feng Cao, Katie L. Davis and William S.M. Wold of the Department of Molecular Microbiology and Immunology at Saint Louis University School of Medicine. Morrison and Tavis hold a U.S.
patent application that covers the inhibitors they investigated. The work was funded by seed grants from the Saint Louis University Department of Molecular Microbiology and Immunology, the Friends of the Saint Louis University Liver Center and the Saint Louis University School of Medicine. Established in 1836, Saint Louis University School of Medicine has the distinction of awarding the first medical degree west of the Mississippi River. The school educates physicians and biomedical scientists, conducts medical research, and provides health care on a local, national and international level. Research at the school seeks new cures and treatments in five key areas: infectious disease, liver disease, cancer, heart/lung disease, and aging and brain disorders.